心血管事件对支气管切除的影响:系统性审查和元分析
Andrea Gramegna1,2, Ivan Barone1,2, Gianfranco Alicandro1,3
1Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
ERJ open research
|October 1, 2024
概括
患有支气管切除症的人面临患冠心病和中风的风险明显更高. 这项研究强调,迫切需要提高对支气管病患者心血管健康的认识和预防策略.
科学领域:
- 肺部医学 肺部医学
- 心脏病学 心脏病学
- 流行病学 流行病学
背景情况:
- 支气管切除症是一种慢性炎症性呼吸道疾病,患病率越来越高.
- 伴随性疾病,特别是心血管疾病,在支气管切除症患者中很常见.
- 心血管疾病与支气管切除症的不良临床结果有关.
研究的目的:
- 为了确定支气管和冠状动脉心脏病之间的综合关联.
- 为了确定支气管和中风之间的聚合关联.
- 系统地审查和对支气管切除和心血管事件的科学证据进行元分析.
主要方法:
- 系统审查和对研究的元分析,截至2023年10月.
- 包括9项研究,包括22239名患者.
- 使用固定效应模型和纽卡斯尔-太华尺度进行质量评估的元分析.
主要成果:
- 冠状动脉心脏病的综合危险比为1.42.
- 脑血管中风的综合危险比为1.71.
- 根据三项高质量的队列研究得出的结论.
结论:
- 支气管切除与显著增加的心血管风险有关.
- 对受影响个体来说,提高意识和预防策略至关重要.
- 需要进一步的研究,以了解支气管和心血管疾病之间联系的潜在机制.
相关概念视频
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K
Chronic Obstructive Pulmonary Disease
1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
COPD: Management Using Bronchodilators and Corticosteroids
185
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
185
COPD: Pathogenesis and Clinical Features
242
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
242
Heart Failure Drugs: β-Blockers
320
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
320


